% | $
Quotes you view appear here for quick access.

Geron Corporation Message Board

  • buffdaddynj buffdaddynj Dec 18, 2013 7:26 PM Flag

    The future of Geron

    Geron's future
    Geron is also busy looking into additional hematological indications for imetelstat. My take is that management wants to make imetelstat a one-stop shop for hematological malignancies in order to give it multiple potential routes to blockbuster status.

    Even so, I think management's ultimate goal is to make Geron an attractive buyout target. While it's certainly easy to draw comparisons to Gilead Sciences buyout of YM Biosciences for its mid-stage myelofibrosis drug, Foolish investors would be wise to look into Scarlett's track record as a CEO.

    Basically, Scarlett is famous for selling his companies to the highest bidder. In short, I think Geron is a strong buyout candidate going forward, especially if imetelstat continues to show promise as a treatment for myelofibrosis.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
4.01-0.04(-0.99%)Aug 3 4:00 PMEDT